| CPHI Stock | | | USD 0.20 0.01 5.26% |
This module uses fundamental data of China Pharma to approximate its Piotroski F score. China Pharma F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of China Pharma Holdings. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about China Pharma financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
China Pharma Altman Z Score,
China Pharma Correlation,
China Pharma Valuation, as well as analyze
China Pharma Alpha and Beta and
China Pharma Hype Analysis.
As of now, China Pharma's
Long Term Debt is increasing as compared to previous years. The China Pharma's current
Long Term Debt Total is estimated to increase to about 3.5
M, while
Interest Debt Per Share is projected to decrease to 1.37. As of now, China Pharma's
Payables Turnover is increasing as compared to previous years. The China Pharma's current
Research And Ddevelopement To Revenue is estimated to increase to 0.04, while
Price To Sales Ratio is projected to decrease to 0.28.
At this time, it appears that China Pharma's Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
| Change in Return on Assets | |
| Cash Flow Return on Assets | |
| Current Quality of Earnings (accrual) | |
| Long Term Debt Over Assets Change | Higher Leverage| Focus | |
| Change In Outstending Shares | |
China Pharma Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to China Pharma is to make sure China is not a subject of accounting manipulations and runs a healthy internal audit department. So, if China Pharma's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if China Pharma's financial numbers are properly reported.
China Pharma Holdings F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between China Pharma's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards China Pharma in a much-optimized way.
Click cells to compare fundamentals
About China Pharma Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
China Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of China Pharma from analyzing China Pharma's financial statements. These drivers represent accounts that assess China Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of China Pharma's important valuation drivers and their relationship over time.
About China Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China Pharma Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of China Pharma Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether China Pharma Holdings
offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China Pharma's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Pharma Holdings Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on China Pharma Holdings Stock: Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost
the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share | Revenue Per Share | Quarterly Revenue Growth | Return On Assets | Return On Equity |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine
if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.